EX-FILING FEES 4 d515034dexfilingfees.htm EX-FILING FEES EX-FILING FEES

Exhibit 107

Calculation of filing Fee Tables

Form S-8

(Form Type)

Sarepta Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1—Newly Registered Securities

 

               
Security
Type
  Security
Class
Title
  Fee
Calculation
Rule
  Amount
Registered (1)
  Proposed
Maximum
Offering
Price
Per Unit
 

Proposed
Maximum
Aggregate

Offering

Price

 

Fee

Rate

  Amount of
Registration
Fee
               
Equity   Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan, as Amended—Common Stock, par value $0.0001 per share   Other—Rule 457(c) and Rule 457(h)   2,500,000 (2)   $104.09 (3)   $260,225,000.00   0.00011020   $28,676.80
               
Equity   Sarepta Therapeutics, Inc. Amended and Restated 2013 Employee Stock Purchase Plan—Common Stock, par value $0.0001 per share   Other—Rule 457(c) and Rule 457(h)   300,000 (4)   $104.09 (3)   $31,227,000.00   0.00011020   $3,441.22
         
Total Offering Amounts     $291,452,000.00     $32,118.02
         
Total Fee Offsets        
         
Net Fees Due               $32,118.02

 

(1)

Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, this Registration Statement on Form S-8 (the “Registration Statement”) shall also cover shares of the Registrant’s common stock that become issuable under the Plans to prevent dilution as a result of any stock dividend, stock split, recapitalization or similar transaction.

(2)

Represents 2,500,000 shares of common stock reserved for future issuance under the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan, as amended, as of the date of the initial filing of this Registration Statement.

(3)

Estimated solely for the purpose of determining the registration fee pursuant to Rule 457(c) and 457(h) under the Securities Act, the “proposed maximum offering price per share” is calculated based on the average of the high and low prices for the Registrant’s common stock as reported on the Nasdaq Global Select Market on July 26, 2023.

(4)

Represents 300,000 shares of common stock reserved for future issuance under the Sarepta Therapeutics, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (as amended and restated on June 27, 2016 and amended on June 6, 2019) as of the date of the initial filing of this Registration Statement.